Halozyme Therapeutics Director Matthew L. Posard sold $570,133.70 worth of shares on Aug 14.

Halozyme Therapeutics Director Matthew L. Posard sold 9,881 shares of the company's stock for $570,133.70 on Aug 14, with remaining shares valued at $4.03M. The biopharmaceutical firm reported a 36.94% net margin, 225.71% ROE, and EPS of $0.91 for the quarter, surpassing analyst estimates. The company has a market cap of $7.56B, P/E 24.65, beta 1.27.

August 17, 2024
4 Articles

Further Reading